Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028433 | 1.00 | KDM6B (0.51) | KDM6BHSD17B10ALOX15KDM4ERECQL | |
| SCHEMBL6574091 | 0.96 | TRPV1 (0.54) | KDM6BHSD17B10ALOX15KDM4ERECQL | |
| SCHEMBL8519244 | 0.96 | TRPV1 (0.54) | KDM6BHSD17B10ALOX15KDM4ERECQL | |
| SCHEMBL31268016 | 0.95 | TRPV1 (0.56) | KDM6BHSD17B10ALOX15KDM4ERECQL | |
| SCHEMBL29652186 | 0.95 | TRPV1 (0.56) | KDM6BHSD17B10ALOX15KDM4ERECQL | |
| SCHEMBL29759443 | 0.92 | KDM6B (0.54) | KDM6BHSD17B10ALOX15KDM4ERECQL | |
| SCHEMBL22364280 | 0.92 | KDM6B (0.54) | KDM6BHSD17B10ALOX15KDM4ERECQL | |
| SCHEMBL31757523 | 0.88 | MAPT (0.56) | HSD17B10ALOX15KDM4EHIF1AUSP2 | |
| SCHEMBL22364281 | 0.85 | KDM6B (0.57) | KDM6BHSD17B10ALOX15KDM4ERECQL | |
| SCHEMBL7433937 | 0.85 | KDM6B (0.57) | KDM6BHSD17B10ALOX15KDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689027-A1 | EFFICIENT, LOW-ENERGY, LOW WASTE ALKYLATION AND ARYLATION METHOD FOR PRODUCING SAFE, ENVIROMENTALLY-FRIENDLY DISUBSTITUTED DIPHENYLAMINE ANTIOXIDANTS | LANXESS Corporation (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024206388-A1 | EFFICIENT, LOW-ENERGY, LOW WASTE ALKYLATION AND ARYLATION METHOD FOR PRODUCING SAFE, ENVIROMENTALLY-FRIENDLY DISUBSTITUTED DIPHENYLAMINE ANTIOXIDANTS | LANXESS CORPORATION (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240159780-A1 | PREDICTION OF AMOUNT OF IN VIVO DOPAMINE ETC., AND APPLICATION THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20230312510-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIVERSITY OF DELHI (IN) | 2023-10-05 | — | — | US | disclosed |
| US-20230157595-A1 | LEVODOPA SENSOR FOR TIGHT TUNING OF DOSAGE | MEDTRONIC, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4178564-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | The McLean Hospital Corporation (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-115843247-A | Compounds and methods for treating neurodegenerative diseases | 麦克莱恩医院公司 | 2023-03-24 | — | — | CN | disclosed |
| US-11589785-B2 | Levodopa sensor for tight tuning of dosage | MEDTRONIC, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-4103060-A1 | LEVODOPA SENSOR FOR TIGHT TUNING OF DOSAGE | Medtronic, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11464756-B1 | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof | DARM JERRY (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2022191332-A1 | PREDICTION OF AMOUNT OF IN VIVO DOPAMINE ETC., AND APPLICATION THEREOF | 住友ファーマ株式会社 | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312510-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NCOR1, NLN, NCOR2 | KDM6B 1615/4885HSD17B10 1448/4885ALOX15 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.